Nasal Vaccine for Alzheimer’s to be tested on People
Boston hospital to conduct Human Trials
A Boston hospital will conduct human trials to test the safety and efficacy of a vaccine to counter Alzheimer’s disease next month. It will mark the first clinical trial of a nasal vaccine for the dementia-causing disorder.
They will receive varying doses over six months, starting in early December, with researchers doing blood testing to determine the appropriate dosage, Dr. Howard Weiner told the Boston Globe newspaper. He called the trial a “remarkable milestone” that follows 20 years of research.
If clinical trials in humans show that the vaccine is safe and effective, this could represent a nontoxic treatment for people with Alzheimer’s, and it could also be given early to help prevent Alzheimer’s in people at risk.
According to the hospital’s statement, the vaccine uses Protollin, a substance that activates the body’s immune system by signaling white blood cells in nearby lymph nodes to travel to the brain and clear out the disease’s “hallmark” beta-amyloid plaques.
Although the hospital noted that Protollin has been found to be safe in other vaccines, the researchers will have to observe how it impacts the patients’ immune response and its effects on white blood cells. This will partly “determine the safety and tolerability of the nasal vaccine” in the trial.
Following the six-month period, there will be a trial of 150 patients who will be “treated for years” with the aim of getting a dose every month for the first year, Dr. Weiner told Fox News.
According to several calculations, less than 10% of drugs entering initial trials go on to win regulatory approval. Problems can arise even after the approval process – as was seen earlier this year when independent advisers raised concerns over the side effects of ‘Aduhelm’, an FDA-approved drug for Alzheimer’s.
_________
RELATED FROM RT
Latest scientific discovery may lead to cure for Alzheimer’s
*********
(TLB) published this article from RT-USA News
Header featured image (edited) credit: Nurse w/Vax/© Getty Images / miljko
••••
••••
Stay tuned to …
••••
The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)
••••
Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.
••••
Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
••••
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.
Leave a Reply